140 related articles for article (PubMed ID: 9670855)
1. Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein.
McIntosh KR; Linsley PS; Bacha PA; Drachman DB
J Neuroimmunol; 1998 Jul; 87(1-2):136-46. PubMed ID: 9670855
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis.
McIntosh KR; Linsley PS; Drachman DB
Cell Immunol; 1995 Nov; 166(1):103-12. PubMed ID: 7585970
[TBL] [Abstract][Full Text] [Related]
3. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
4. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis.
Wang HB; Shi FD; Li H; Chambers BJ; Link H; Ljunggren HG
J Immunol; 2001 May; 166(10):6430-6. PubMed ID: 11342669
[TBL] [Abstract][Full Text] [Related]
5. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.
Shi FD; Bai XF; Li HL; Huang YM; Van der Meide PH; Link H
Clin Exp Immunol; 1998 Mar; 111(3):506-12. PubMed ID: 9528890
[TBL] [Abstract][Full Text] [Related]
6. Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies.
Balcer LJ; McIntosh KR; Nichols JC; Drachman DB
J Neuroimmunol; 1991 Feb; 31(2):115-22. PubMed ID: 1991819
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
Okumura S; McIntosh K; Drachman DB
Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
[TBL] [Abstract][Full Text] [Related]
8. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
9. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
10. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
Im SH; Barchan D; Fuchs S; Souroujon MC
J Clin Invest; 1999 Dec; 104(12):1723-30. PubMed ID: 10606626
[TBL] [Abstract][Full Text] [Related]
11. B cell autoimmunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis.
Wang ZY; Link H; Qiao J; Olsson T; Huang WX
J Neuroimmunol; 1993 Jun; 45(1-2):103-12. PubMed ID: 8331155
[TBL] [Abstract][Full Text] [Related]
12. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
13. 'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis; implications for the design of specific immunotherapies.
Ohtsuru I; Matsuo H; Fukudome T; Suenaga A; Tsujihata M; Nagataki S
Clin Exp Immunol; 1995 Dec; 102(3):462-7. PubMed ID: 8536358
[TBL] [Abstract][Full Text] [Related]
14. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis.
Im SH; Barchan D; Souroujon MC; Fuchs S
J Immunol; 2000 Oct; 165(7):3599-605. PubMed ID: 11034361
[TBL] [Abstract][Full Text] [Related]
15. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells.
Xiao BG; Duan RS; Link H; Huang YM
Cell Immunol; 2003 May; 223(1):63-9. PubMed ID: 12914759
[TBL] [Abstract][Full Text] [Related]
16. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
Zoda T; Yeh TM; Krolick KA
J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
[TBL] [Abstract][Full Text] [Related]
17. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.
Wang ZY; Qiao J; Link H
J Neuroimmunol; 1993 May; 44(2):209-14. PubMed ID: 8505410
[TBL] [Abstract][Full Text] [Related]
18. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Huang J; Olsson T; He B; Link H
J Neurol Sci; 1995 Feb; 128(2):167-74. PubMed ID: 7537794
[TBL] [Abstract][Full Text] [Related]
19. Clonotypic analysis of the antibody response to the acetylcholine receptor in experimental autoimmune myasthenia gravis.
Brown RM; Krolick KA
J Neuroimmunol; 1988 Sep; 19(3):205-22. PubMed ID: 3261738
[TBL] [Abstract][Full Text] [Related]
20. Prevention of experimental autoimmune myasthenia gravis in rats by fetal alpha-fetoprotein-rich fractions.
Brenner T; Zielinski A; Argov Z; Abramsky O
Tumour Biol; 1984; 5(5):263-74. PubMed ID: 6085187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
